NEIL KUMAR - 19 Feb 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
19 Feb 2026
Net transactions value
-$2,002,717
Form type
4
Filing time
23 Feb 2026, 16:32:04 UTC
Previous filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kumar Neil Chief Executive Officer, Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 23 Feb 2026 0001742485

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale $1,344,190 -18,923 -7.2% $71.03 243,581 19 Feb 2026 Direct F1, F2
transaction BBIO Common Stock Sale $614,702 -8,528 -3.5% $72.08 235,053 19 Feb 2026 Direct F1, F3
transaction BBIO Common Stock Sale $43,826 -602 -0.26% $72.80 234,451 19 Feb 2026 Direct F1, F4
holding BBIO Common Stock 675,686 19 Feb 2026 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F5
holding BBIO Common Stock 4,478,447 19 Feb 2026 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
F2 Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3 Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4 Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.